{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:17:36Z","timestamp":1781630256728,"version":"3.54.5"},"reference-count":16,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>A female patient in her mid-20s presented with fevers, rash and polyarthralgia and was ultimately diagnosed with macrophage activation syndrome (MAS), a widely recognised form of secondary haemophagocytic lymphohistiocytosis in the setting of autoinflammatory disease such as adult-onset Still\u2019s disease. Extensive infectious and malignancy workup was negative. Her clinical course was complicated by persistently active disease despite initial immunomodulator therapies, including corticosteroids and anti-interleukin-1 therapy (anakinra). Further escalation of therapy with tocilizumab and etoposide yielded insufficient, partial improvement. Given the refractory nature of her condition, we initiated treatment with emapalumab, an anti-interferon-\u03b3 antibody, which led to significant symptom control. We subsequently added Janus kinase inhibitor (JAK), ruxolitinib, and continued anakinra until complete resolution of symptoms and normalisation of laboratory values. The patient was then discharged on a stable dose of ruxolitinib, anakinra and prednisone. This case illustrates the therapeutic challenges in managing refractory MAS and highlights the emerging role of targeted therapies such as emapalumab and JAK inhibitors in treatment-refractory cases.<\/jats:p>","DOI":"10.1136\/bcr-2025-269827","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:15:17Z","timestamp":1771478117000},"page":"e269827","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Refractory macrophage activation syndrome in adult-onset Still\u2019s disease: response to interferon-\u03b3 blockade and JAK inhibition"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-8375","authenticated-orcid":false,"given":"Moath","family":"Bani Salem","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, HCA Florida North Florida Hospital, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6220-0836","authenticated-orcid":false,"given":"Shirley","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026021821151283000_19.2.e269827.1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic Lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021821151283000_19.2.e269827.2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14740338.2020.1839411","article-title":"Current treatment options and safety considerations when treating adult-onset Still\u2019s disease","volume":"19","author":"Cavalli","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2026021821151283000_19.2.e269827.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key006"},{"key":"2026021821151283000_19.2.e269827.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X"},{"key":"2026021821151283000_19.2.e269827.5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjh.14147","article-title":"Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"key":"2026021821151283000_19.2.e269827.6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12293"},{"key":"2026021821151283000_19.2.e269827.7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21660"},{"key":"2026021821151283000_19.2.e269827.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300046"},{"key":"2026021821151283000_19.2.e269827.9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043625"},{"key":"2026021821151283000_19.2.e269827.10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/art.43052","article-title":"Macrophage Activation Syndrome","volume":"77","author":"Nigrovic","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026021821151283000_19.2.e269827.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100766"},{"key":"2026021821151283000_19.2.e269827.12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/art.42636","article-title":"The 2022 EULAR\/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis\/Macrophage Activation Syndrome (HLH\/MAS)","volume":"75","author":"Shakoory","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026021821151283000_19.2.e269827.13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/keae391","article-title":"Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project","volume":"64","author":"Baldo","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026021821151283000_19.2.e269827.14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1301","article-title":"Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis","volume":"146","author":"Jianguo","year":"2020","journal-title":"Pediatrics"},{"key":"2026021821151283000_19.2.e269827.15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.2023022281","article-title":"Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation","volume":"143","author":"B\u00f6hm","year":"2024","journal-title":"Blood"},{"key":"2026021821151283000_19.2.e269827.16","first-page":"2515","article-title":"Outcome of primary hemophagocytic lymphohistiocytosis: a report on 143 patients from the Italian Registry","volume":"109","author":"Pegoraro","year":"2024","journal-title":"Haematologica"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:15:19Z","timestamp":1771478119000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bcr-2025-269827"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269827","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}